(Q35187824)

English

Phase I trial of lenalidomide and CCI-779 in patients with relapsed multiple myeloma: evidence for lenalidomide-CCI-779 interaction via P-glycoprotein

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

Phase I trial of lenalidomide and CCI-779 in patients with relapsed multiple myeloma: evidence for lenalidomide-CCI-779 interaction via P-glycoprotein (English)

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

phase I clinical trial

0 references

12

object named as

Larry J Schaaf

0 references

20

object named as

John C Byrd

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

author name string

Craig C Hofmeister

1

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

Xiaoxia Yang

2

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

Flavia Pichiorri

3

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

Ping Chen

4

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

Darlene M Rozewski

5

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

Amy J Johnson

6

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

Seungsoo Lee

7

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

Zhongfa Liu

8

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

Celia L Garr

9

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

Erinn M Hade

10

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

Jia Ji

11

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

Larry J Schaaf

12

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

Don M Benson

13

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

Eric H Kraut

14

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

William J Hicks

15

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

Kenneth K Chan

16

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

Ching-Shih Chen

17

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

Sherif S Farag

18

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

Michael R Grever

19

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

Mitch A Phelps

21

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

language of work or name

0 references

publication date

8 August 2011

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

Journal of Clinical Oncology

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

29

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

25

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

3427-3434

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

Lenalidomide targets clonogenic side population in multiple myeloma: pathophysiologic and clinical implications

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3164245

28 July 2018

Phase I study of oral lenalidomide in patients with refractory metastatic cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3164245

28 July 2018

DEPTOR is an mTOR inhibitor frequently overexpressed in multiple myeloma cells and required for their survival

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3164245

28 July 2018

Phase II trial of temsirolimus in patients with relapsed or refractory multiple myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3164245

28 July 2018

Role of active drug transporters in refractory multiple myeloma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3164245

28 July 2018

Lenalidomide in combination with dexamethasone for the treatment of multiple myeloma after one prior therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3164245

28 July 2018

Lenalidomide down-regulates the CD20 antigen and antagonizes direct and antibody-dependent cellular cytotoxicity of rituximab on primary chronic lymphocytic leukemia cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3164245

28 July 2018

AKT activity regulates the ability of mTOR inhibitors to prevent angiogenesis and VEGF expression in multiple myeloma cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3164245

28 July 2018

P-glycoprotein restricts access of cortisol and dexamethasone to the glucocorticoid receptor in placental BeWo cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3164245

28 July 2018

Population pharmacokinetics of CCI-779: correlations to safety and pharmacogenomic responses in patients with advanced renal cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3164245

28 July 2018

Molecular targeting: PI3 kinase pathway

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3164245

28 July 2018

In vivo antitumor effects of the mTOR inhibitor CCI-779 against human multiple myeloma cells in a xenograft model

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3164245

28 July 2018

Overcoming Drug Resistance in Multiple Myeloma: The Emergence of Therapeutic Approaches to Induce Apoptosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3164245

28 July 2018

AKT activity determines sensitivity to mammalian target of rapamycin (mTOR) inhibitors by regulating cyclin D1 and c-myc expression

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3164245

28 July 2018

The phosphatidylinositol 3-Kinase AKT pathway in human cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3164245

28 July 2018

Current drug therapy for multiple myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3164245

28 July 2018

Drug resistance in multiple myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3164245

28 July 2018

Drug resistance in multiple myeloma: novel therapeutic targets within the malignant clone.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3164245

28 July 2018

Differential modulation of P-glycoprotein expression by dexamethasone and 3-methylcholanthrene in rat hepatocyte primary cultures

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3164245

28 July 2018

Immunosuppressants FK506 and rapamycin function as reversal agents of the multidrug resistance phenotype

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3164245

28 July 2018

Human P-glycoprotein transports cortisol, aldosterone, and dexamethasone, but not progesterone

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3164245

28 July 2018

Modulation of multidrug-resistant multiple myeloma by cyclosporin. The Leukaemia Group of the EORTC and the HOVON

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3164245

28 July 2018

Prediction of creatinine clearance from serum creatinine

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3164245

28 July 2018

The clinical utility of lenalidomide in multiple myeloma and myelodysplastic syndromes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3164245

27 September 2018

The novel orally bioavailable inhibitor of phosphoinositol-3-kinase and mammalian target of rapamycin, NVP-BEZ235, inhibits growth and proliferation in multiple myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3164245

27 September 2018

Lenalidomide: in vitro evaluation of the metabolism and assessment of cytochrome P450 inhibition and induction

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3164245

27 September 2018

Development and validation of a highly sensitive liquid chromatography/mass spectrometry method for simultaneous quantification of lenalidomide and flavopiridol in human plasma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3164245

27 September 2018

A phase I trial of lenalidomide in patients with recurrent primary central nervous system tumors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3164245

27 September 2018

Pharmacokinetics of lenalidomide in subjects with various degrees of renal impairment and in subjects on hemodialysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3164245

27 September 2018

Morphological and functional changes in p-glycoprotein during dexamethasone-induced hepatomegaly.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3164245

27 September 2018

A phase I and pharmacokinetic study of temsirolimus (CCI-779) administered intravenously daily for 5 days every 2 weeks to patients with advanced cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3164245

27 September 2018

International uniform response criteria for multiple myeloma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3164245

27 September 2018

Combination of the mTOR inhibitor rapamycin and CC-5013 has synergistic activity in multiple myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3164245

27 September 2018

Phase I/pharmacokinetic study of CCI-779 in patients with recurrent malignant glioma on enzyme-inducing antiepileptic drugs.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3164245

27 September 2018

Rapamycin sensitizes multiple myeloma cells to apoptosis induced by dexamethasone.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3164245

27 September 2018

Ritonavir and dexamethasone induce expression of CYP3A and P-glycoprotein in rats

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3164245

27 September 2018

Enhanced sensitivity of multiple myeloma cells containing PTEN mutations to CCI-779.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3164245

27 September 2018

Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3164245

27 September 2018

Metabolism and transport of the macrolide immunosuppressant sirolimus in the small intestine.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3164245

27 September 2018

Regulation by dexamethasone of P-glycoprotein expression in cultured rat hepatocytes.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3164245

27 September 2018

Reversal of multidrug resistance in Chinese hamster ovary cells by the immunosuppressive agent rapamycin.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3164245

27 September 2018

Cytochrome P-450 3A enzymes are responsible for biotransformation of FK506 and rapamycin in man and rat

1 reference

https://pubmed.ncbi.nlm.nih.gov/21825263

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effect of dexamethasone on the intestinal first-pass metabolism of indinavir in rats: evidence of cytochrome P-450 3A [correction of P-450 A] and p-glycoprotein induction

1 reference

https://pubmed.ncbi.nlm.nih.gov/21825263

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Lenalidomide: a novel anticancer drug with multiple modalities

1 reference

https://pubmed.ncbi.nlm.nih.gov/21825263

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1200/JCO.2010.32.4962

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q35187824&oldid=1977168810"